Amalgam Rx
Prior to founding Amalgam Rx, Mr. Sysko was the Co-Founder, CEO, and Chairman of WellDoc. The company helped pioneer the mobile health (“mHealth”) industry with one of the earliest FDA cleared, clinically-validated (through multiple randomized controlled trials), prescribed and reimbursed digital health products. The American Diabetes Association has listed WellDoc’s product, BlueStar, as the first and only Mobile Prescription Therapy. WellDoc has been recognized by Forbes as “One of America’s Most Promising Companies,” by the NASDAQ as “One of the Next Great Consumer Brands,” and by SmartCEO as a “Future 50 Fastest Growing Company.” Mr. Sysko has extensive background in helping to launch and develop start-up companies.
Amalgam Rx
Amalgam Rx brings together life sciences companies, payers & providers. By leveraging their +7 Billion RWE data points, creating and distributing exceptional digital medicine products, patient support programs, combination products, and clinical decision support, Amalgam identifies patients in need, increases access, improves adherence, strengthens outcomes, and reduces costs of care.